Page 4 - Typhis Typhi News Today

Typhoid fever is an infectious febrile illness caused by Salmonella typhi that is rare in the United States but is endemic in regions of South Asia and Africa. Typhoid fever initially presents with nonspecific symptoms such as fever, malaise, and abdominal pain. We describe a case of typhoid fever in an adult in the United States with recent travel to Mexico. After a nonspecific presentation, the patient developed Faget sign and computed tomography (CT) of the abdomen revealed mesenteric adenit...

Researchers from Yale University, University of Basel, University of Antwerp, CDDEP and other institutions recently published 'Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modeling study' in The Lancet Infectious Diseases.

Typhoid fever is a systemic infection caused by the bacterium Salmonella enterica serovar Typhi (S. Typhi). Antimicrobials are the mainstay of typhoid disease control and effective antimicrobial therapy can reduce the rate of complications from 10–30% down to 1%. A new conjugate vaccine has recently been pre-qualified by the World Health Organization (WHO) and national immunisation programmes are currently being considered by many countries where the disease is endemic.

Monday, 05 Apr 2021 03:06 PM MYT BY TAN MEI ZI A Ramadan bazaar trader makes ‘murtabak’ at his home during the movement control order in Shah Alam April 15, 2020. — Reuters pic Subscribe to our Telegram channel for the latest updates on news you need to know. PETALING JAYA, April 5 — Malaysian doctors are calling on food handlers to ensure they are vaccinated against typhoid before the Ramadan month kicks off. Early prevention is necessary to prevent an outbreak from occurring especiall...

IVI-SKs new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate T...